Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more
Biohit Oyj B (BIOBV) - Net Assets
Latest net assets as of December 2025: €14.90 Million EUR
Based on the latest financial reports, Biohit Oyj B (BIOBV) has net assets worth €14.90 Million EUR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€19.80 Million) and total liabilities (€4.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €14.90 Million |
| % of Total Assets | 75.25% |
| Annual Growth Rate | -7.26% |
| 5-Year Change | 104.11% |
| 10-Year Change | 38.6% |
| Growth Volatility | 67.16 |
Biohit Oyj B - Net Assets Trend (2000–2025)
This chart illustrates how Biohit Oyj B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biohit Oyj B (2000–2025)
The table below shows the annual net assets of Biohit Oyj B from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €14.90 Million | +22.13% |
| 2024-12-31 | €12.20 Million | +29.43% |
| 2023-12-31 | €9.43 Million | +26.39% |
| 2022-12-31 | €7.46 Million | +2.16% |
| 2021-12-31 | €7.30 Million | -16.12% |
| 2020-12-31 | €8.70 Million | -40.31% |
| 2019-12-31 | €14.58 Million | -8.26% |
| 2018-12-31 | €15.89 Million | -7.84% |
| 2017-12-31 | €17.24 Million | +60.40% |
| 2016-12-31 | €10.75 Million | +4.27% |
| 2015-12-31 | €10.31 Million | -18.67% |
| 2014-12-31 | €12.68 Million | -43.53% |
| 2013-12-31 | €22.45 Million | -36.75% |
| 2012-12-31 | €35.49 Million | -32.84% |
| 2011-12-31 | €52.85 Million | +306.41% |
| 2010-12-31 | €13.00 Million | +1.99% |
| 2009-12-31 | €12.75 Million | +2.06% |
| 2008-12-31 | €12.49 Million | +5.49% |
| 2007-12-31 | €11.84 Million | -11.73% |
| 2006-12-31 | €13.41 Million | -5.86% |
| 2005-12-31 | €14.25 Million | +0.79% |
| 2004-12-31 | €14.14 Million | +0.27% |
| 2003-12-31 | €14.10 Million | -5.34% |
| 2002-12-31 | €14.90 Million | -8.80% |
| 2001-12-31 | €16.33 Million | -83.34% |
| 2000-12-31 | €98.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biohit Oyj B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 930000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €9.30 Million | 62.42% |
| Common Stock | €2.40 Million | 16.11% |
| Other Comprehensive Income | €-100.00K | -0.67% |
| Other Components | €3.30 Million | 22.15% |
| Total Equity | €14.90 Million | 100.00% |
Biohit Oyj B Competitors by Market Cap
The table below lists competitors of Biohit Oyj B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nova EYE Medical Ltd
AU:EYE
|
$19.87 Million |
|
Dedicare AB
LSE:0P3K
|
$19.87 Million |
|
Chander Electronics Corp.
TWO:8068
|
$19.87 Million |
|
Prime Financial Group Ltd
AU:PFG
|
$19.88 Million |
|
Buriram Sugar Public Company Limited
BK:BRR
|
$19.86 Million |
|
Elauwit Connection, Inc. Common Stock
NASDAQ:ELWT
|
$19.86 Million |
|
FARMAE S.P.A.
F:U5Y
|
$19.85 Million |
|
Force MOS Technology Co., LTD.
TWO:4923
|
$19.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biohit Oyj B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 12,300,000 to 14,900,000, a change of 2,600,000 (21.1%).
- Net income of 2,700,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 3,407,000.
- Other factors increased equity by 3,307,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €2.70 Million | +18.12% |
| Other Comprehensive Income | €-3.41 Million | -22.87% |
| Other Changes | €3.31 Million | +22.19% |
| Total Change | €- | 21.14% |
Book Value vs Market Value Analysis
This analysis compares Biohit Oyj B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.50x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 2.24x to 2.50x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | €1.09 | €2.45 | x |
| 2005-12-31 | €1.10 | €2.45 | x |
| 2006-12-31 | €0.97 | €2.45 | x |
| 2007-12-31 | €0.86 | €2.45 | x |
| 2008-12-31 | €0.97 | €2.45 | x |
| 2009-12-31 | €0.92 | €2.45 | x |
| 2010-12-31 | €1.01 | €2.45 | x |
| 2011-12-31 | €3.64 | €2.45 | x |
| 2012-12-31 | €2.61 | €2.45 | x |
| 2013-12-31 | €1.61 | €2.45 | x |
| 2014-12-31 | €0.87 | €2.45 | x |
| 2015-12-31 | €0.70 | €2.45 | x |
| 2016-12-31 | €0.71 | €2.45 | x |
| 2017-12-31 | €1.15 | €2.45 | x |
| 2018-12-31 | €1.06 | €2.45 | x |
| 2019-12-31 | €0.97 | €2.45 | x |
| 2020-12-31 | €0.58 | €2.45 | x |
| 2021-12-31 | €0.49 | €2.45 | x |
| 2022-12-31 | €0.49 | €2.45 | x |
| 2023-12-31 | €0.62 | €2.45 | x |
| 2024-12-31 | €0.81 | €2.45 | x |
| 2025-12-31 | €0.98 | €2.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biohit Oyj B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.12%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.20%
- • Asset Turnover: 0.79x
- • Equity Multiplier: 1.33x
- Recent ROE (18.12%) is above the historical average (-1.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -1.20% | -0.63% | 1.17x | 1.61x | €-1.58 Million |
| 2005 | -1.59% | -0.79% | 1.03x | 1.95x | €-1.65 Million |
| 2006 | -6.25% | -2.67% | 1.15x | 2.04x | €-2.18 Million |
| 2007 | -12.68% | -4.59% | 1.20x | 2.31x | €-2.69 Million |
| 2008 | 7.18% | 2.58% | 1.28x | 2.17x | €-352.20K |
| 2009 | 3.04% | 1.09% | 1.29x | 2.15x | €-887.90K |
| 2010 | 0.47% | 0.15% | 1.36x | 2.26x | €-1.24 Million |
| 2011 | 71.36% | 94.46% | 0.56x | 1.35x | €32.43 Million |
| 2012 | -10.30% | -178.52% | 0.05x | 1.13x | €-7.21 Million |
| 2013 | -26.36% | -171.41% | 0.12x | 1.26x | €-8.16 Million |
| 2014 | -9.16% | -26.61% | 0.30x | 1.14x | €-2.43 Million |
| 2015 | -28.29% | -48.21% | 0.52x | 1.14x | €-3.95 Million |
| 2016 | -30.65% | -40.21% | 0.63x | 1.21x | €-4.37 Million |
| 2017 | 35.60% | 68.37% | 0.48x | 1.10x | €4.41 Million |
| 2018 | -13.48% | -21.58% | 0.56x | 1.13x | €-3.73 Million |
| 2019 | -9.71% | -14.09% | 0.58x | 1.19x | €-2.87 Million |
| 2020 | -38.06% | -46.50% | 0.66x | 1.24x | €-4.18 Million |
| 2021 | -20.55% | -16.02% | 0.97x | 1.32x | €-2.23 Million |
| 2022 | 8.06% | 5.49% | 0.99x | 1.48x | €-144.70K |
| 2023 | 19.64% | 14.16% | 1.01x | 1.37x | €908.50K |
| 2024 | 21.14% | 18.18% | 0.92x | 1.26x | €1.37 Million |
| 2025 | 18.12% | 17.20% | 0.79x | 1.33x | €1.21 Million |
Industry Comparison
This section compares Biohit Oyj B's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $46,995,867
- Average return on equity (ROE) among peers: 4.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biohit Oyj B (BIOBV) | €14.90 Million | -1.20% | 0.33x | $19.87 Million |
| BBS-Bioactive Bone Substitutes Oyj (BONEH) | $4.42 Million | 8.60% | 1.53x | $854.55K |
| Modulight Oyj (MODU) | $76.15 Million | -6.65% | 0.15x | $17.65 Million |
| Nexstim Oyj (NXTMH) | $-294.27K | 0.00% | 0.00x | $35.65 Million |
| Revenio Group Corporation (REG1V) | $107.71 Million | 17.17% | 0.31x | $481.80 Million |